Isabelle Cloutier
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Isabelle Cloutier has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Alexandra Porlier
Centre de Recherche, Institut Universitaire de Cardiologie et de Pneumologie de Québec, Université Laval (CRIUCPQ-ULaval), 2725, Chemin Sainte-Foy, Quebec City, QC G1V 4G5, Canada
1 shared publication - Anick Bérard
Research Center, CHU Sainte-Justine, Montreal, Canada
1 shared publication - Audrey Vachon
Centre de Recherche, Institut Universitaire de Cardiologie et de Pneumologie de Québec, Université Laval (CRIUCPQ-ULaval), 2725, Chemin Sainte-Foy, Quebec City, QC G1V 4G5, Canada
1 shared publication - Benoit Drolet
Centre de Recherche, Institut Universitaire de Cardiologie et de Pneumologie de Québec, Université Laval (CRIUCPQ-ULaval), 2725, Chemin Sainte-Foy, Quebec City, QC G1V 4G5, Canada
1 shared publication - Chantale Simard
Faculté de Pharmacie, Université Laval, Québec, QC G1V 0A6, Canada
1 shared publication - Fernanda Raphael Escobar Gimenes
Ribeirão Preto College of Nursing (EERP), University of São Paulo (USP), Ribeirão Preto 14040-902, Brazil
1 shared publication
Latest Publications
- Open Access
Stability of Injectable Ceftobiprole Medocaril (Zevtera®) in PVC Bags and in the Intermate® Infusion System: A Technological Turning Point for Ambulatory Administration of Intravenous Antibiotics
Background: Ceftobiprole medocaril (Zevtera®) is an injectable broad-spectrum antibiotic. Objective: We aim to show that ceftobiprole initiated in hospital may be continued at home through Outpatient Parenteral Antibiotic Therapy (OPAT). Methods: Solutions of ceftobiprole at 2.0 and 2.8 mg/mL were prepared in PVC bags from 500 mg vials and stored at room temperature (RT) or 4 °C. Each sample was analyzed in triplicate samples using high-performance liquid chromatography (HPLC) at multiple time points over a 120 h period. Additionally, 2.5 mg/mL ceftobiprole solutions were prepared in Intermate® infusion devices (n = 3 preparations) and stored at 4 °C. Samples were collected on multiple days from Day 0 to Day 9, both immediately post-refrigeration and after 8 h at RT and analyzed in triplicate. Results: PVC bag solutions retained ≥90% of their initial concentrations. At RT, residual concentration was 90.9% (2.0 mg/mL) and 92.0% (2.8 mg/mL) after 24 h. At 4 °C, the 2.0 mg/mL formulation retained 90.8% after 120 h, and the 2.8 mg/mL formulation retained 90.2% after 96 h. Intermate® devices stored nine days at 4 °C and exposed to RT for 8 h retained ≥90% of the initial concentration of ceftobiprole (2.5 mg/mL; 93.3% before RT exposure; 91.1% after). Conclusions: Ceftobiprole medocaril exhibits sufficient physicochemical stability for OPAT use in PVC bags and Intermate® infusion device under tested conditions.
Open AccessStability of Injectable Ceftobiprole Medocaril (Zevtera®) in PVC Bags and in the Intermate® Infusion System: A Technological Turning Point for Ambulatory Administration of Intravenous Antibiotics
Background: Ceftobiprole medocaril (Zevtera®) is an injectable broad-spectrum antibiotic. Objective: We aim to show that ceftobiprole initiated in hospital may be continued at home through Outpatient Parenteral Antibiotic Therapy (OPAT). Methods: Solutions of ceftobiprole at 2.0 and 2.8 mg/mL were prepared in PVC bags from 500 mg vials and stored at room temperature (RT) or 4 °C. Each sample was analyzed in triplicate samples using high-performance liquid chromatography (HPLC) at multiple time points over a 120 h period. Additionally, 2.5 mg/mL ceftobiprole solutions were prepared in Intermate® infusion devices (n = 3 preparations) and stored at 4 °C. Samples were collected on multiple days from Day 0 to Day 9, both immediately post-refrigeration and after 8 h at RT and analyzed in triplicate. Results: PVC bag solutions retained ≥90% of their initial concentrations. At RT, residual concentration was 90.9% (2.0 mg/mL) and 92.0% (2.8 mg/mL) after 24 h. At 4 °C, the 2.0 mg/mL formulation retained 90.8% after 120 h, and the 2.8 mg/mL formulation retained 90.2% after 96 h. Intermate® devices stored nine days at 4 °C and exposed to RT for 8 h retained ≥90% of the initial concentration of ceftobiprole (2.5 mg/mL; 93.3% before RT exposure; 91.1% after). Conclusions: Ceftobiprole medocaril exhibits sufficient physicochemical stability for OPAT use in PVC bags and Intermate® infusion device under tested conditions.
- Open Access
- 1 May 2025
- Published by Canadian Science Publishing in Canadian Journal of Physiology and Pharmacology
- Vol. 103 (5) , 172-181
Causality assessment of adverse events by healthcare professionals in an academic hospital setting: a descriptive retrospective study
Assessing the causality of a drug product-related adverse event (AE) is a very important aspect of pharmacovigilance. However, it is unclear whether AEs are investigated for causality in a hospital setting. The aims of this study were to (1) evaluate the proportion of AEs for which causality is sought and (2) list the causality assessment (CA) tools used by healthcare professionals. This retrospective study includes 500 randomized patients (125 patients/year) admitted to a tertiary care academic hospital between 2018 and 2021. Electronic medical records were reviewed and relevant variables were extracted: (1) demographic, (2) hospitalization, (3) drug product, (4) AE, and (5) CA. A descriptive analysis was carried out (median, minimum–maximum, proportion) to characterize our sample. The characteristic of our sample was as follows: median age 69 years old (range: 21–96 years), 43.6% female, median comorbidities/patient 4 (0–12), and median hospital stay of 3 days (1–19). We identified a total of 9568 drug products and 2541 AEs, among these, 302 (8.4%) were serious AEs. No CA ( n = 0) or CA tools ( n = 0) were found in our sample. In this study, we report that no AEs, whether serious or non-serious, were subject to documented CA. Key points: Adverse events among drug users are frequent during hospital stay. Causality assessment of adverse events was poorly documented by healthcare professionals in a hospital setting.
- 1 May 2025
- Published by Canadian Science Publishing in Canadian Journal of Physiology and Pharmacology
- Vol. 103 (5) , 172-181
Open AccessCausality assessment of adverse events by healthcare professionals in an academic hospital setting: a descriptive retrospective study
Assessing the causality of a drug product-related adverse event (AE) is a very important aspect of pharmacovigilance. However, it is unclear whether AEs are investigated for causality in a hospital setting. The aims of this study were to (1) evaluate the proportion of AEs for which causality is sought and (2) list the causality assessment (CA) tools used by healthcare professionals. This retrospective study includes 500 randomized patients (125 patients/year) admitted to a tertiary care academic hospital between 2018 and 2021. Electronic medical records were reviewed and relevant variables were extracted: (1) demographic, (2) hospitalization, (3) drug product, (4) AE, and (5) CA. A descriptive analysis was carried out (median, minimum–maximum, proportion) to characterize our sample. The characteristic of our sample was as follows: median age 69 years old (range: 21–96 years), 43.6% female, median comorbidities/patient 4 (0–12), and median hospital stay of 3 days (1–19). We identified a total of 9568 drug products and 2541 AEs, among these, 302 (8.4%) were serious AEs. No CA ( n = 0) or CA tools ( n = 0) were found in our sample. In this study, we report that no AEs, whether serious or non-serious, were subject to documented CA. Key points: Adverse events among drug users are frequent during hospital stay. Causality assessment of adverse events was poorly documented by healthcare professionals in a hospital setting.